Mein Warenkorb

Fc gamma RIIIA / CD16a

Fc gamma RIIIA / CD16a Molekülinformation

Englischer NameLow affinity immunoglobulin gamma Fc region receptor III-AAnzahl der inverkehr gebrachten Arzneimittel0
Anzahl der klinischen Arzneimittel14Target-AliasIGFR3,FCG3,Fc Fragment Of IgG, Low Affinity IIIa, Receptor For (CD16),Fc Fragment Of IgG, Low Affinity III, Receptor For (CD16),Immunoglobulin G Fc Receptor III,Fc-Gamma Receptor III-2 (CD 16),Neutrophil-Specific Antigen NA,Fc-Gamma Receptor IIIb (CD16),Fc Gamma Receptor III-A,Low Affinity Immunoglobulin Gamma Receptor III-A Fc Fragment,IgG Fc receptor III-2,Low affinity immunoglobulin gamma Fc region receptor III-A,FCGR3,CD16A,Fc-gamma RIII-alpha,FCGR3A,Fc Fragment Of IgG Receptor IIIa,Fc Fragment Of IgG, Low Affinity IIIa, Receptor (CD16a),CD16a Antigen,Fc Gamma Receptor IIIa,Fc-Gamma RIIIa,Fc-Gamma RIII,FcgammaRIIIA,FCGRIII,FcRIIIa,FCR-10,FCRIII,IMD20,CD16
Höchste Forschungs- und EntwicklungsphasePhase 2 Clinical
Englischer NameLow affinity immunoglobulin gamma Fc region receptor III-A
Target-AliasIGFR3,FCG3,Fc Fragment Of IgG, Low Affinity IIIa, Receptor For (CD16),Fc Fragment Of IgG, Low Affinity III, Receptor For (CD16),Immunoglobulin G Fc Receptor III,Fc-Gamma Receptor III-2 (CD 16),Neutrophil-Specific Antigen NA,Fc-Gamma Receptor IIIb (CD16),Fc Gamma Receptor III-A,Low Affinity Immunoglobulin Gamma Receptor III-A Fc Fragment,IgG Fc receptor III-2,Low affinity immunoglobulin gamma Fc region receptor III-A,FCGR3,CD16A,Fc-gamma RIII-alpha,FCGR3A,Fc Fragment Of IgG Receptor IIIa,Fc Fragment Of IgG, Low Affinity IIIa, Receptor (CD16a),CD16a Antigen,Fc Gamma Receptor IIIa,Fc-Gamma RIIIa,Fc-Gamma RIII,FcgammaRIIIA,FCGRIII,FcRIIIa,FCR-10,FCRIII,IMD20,CD16
Anzahl der inverkehr gebrachten Arzneimittel0
Anzahl der klinischen Arzneimittel14
Höchste Forschungs- und EntwicklungsphasePhase 2 Clinical

Fc gamma RIIIA / CD16a Produktliste

  • Attribut

    Protein (7)Cell (5)Kits (2)

  • Produktbibliothek

    Online (14)

  • Spezies

    Human (14)

  • Etikett

    His Tag (3)His Tag & Avi Tag (2)His Tag & SUMO Tag (1)HSA Tag & His Tag (1)- (7)

  • Marker

    Unconjugated (5)Biotin-labeled (2)- (7)

Fc gamma RIIIA / CD16a Molekülhintergrund

CD16 is a low affinity Fc receptor, and has been identified as Fc receptors FcγRIIIa (CD16a) and FcγRIIIb (CD16b). These receptors bind to the Fc portion of IgG antibodies. CD16 encoded by two different highly homologous genes in a cell type-specific manner.CD16 is found on the surface of natural killer cells, neutrophil polymorphonuclear leukocytes, monocytes and macrophages. CD16a antigen is also known as Low affinity immunoglobulin gamma Fc region receptor III-A, Fc-gamma RIII-alpha. CD16b is a low-affinity, GPI-linked receptor expressed by neutrophils and eosinophils, whereas CD16a is an intermediate affinity polypeptide-anchored transmembrane glycoprotein expressed natural killer cells, macrophages, subpopulation of T-cells, immature thymocytes and placentaltrophoblasts.CD16a is involved in phagocytosis, secretion of enzymes and inflammatory mediators, antibody­dependent cytotoxicity and clearance of immune complexes. Aberrant expression or mutations of CD16a is implicated in susceptibility to recurrent viral infections, systemic lupus erythematosus, and alloimmune neonatal neutropenia.

Fc gamma RIIIA / CD16a Molekülalias

FCGR3A,CD16A,FCG3,FCGR3,IGFR3

Antikörperprojekt-Handelsplattform

ProjektnameProjektphaseMolekültypMolekülquelleKrankheitsgebietIndikationen
CD16a VHH - 01PCCMonoclonalNanobodySolid TumorSolid tumor,Hematoma

Klinische Arzneimittelinformation

Englischer NameForschungscodeForschungsphaseFirmaIndikationenKlinische Studie
AcimtamigAFM-13Phase 2 ClinicalThe University Of Texas MD Anderson Cancer CenterHodgkin Disease; Lymphoma, B-Cell; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell, Peripheral; Mycosis Fungoides
Details
IPH-6501IPH-6501; IPH-65Phase 2 ClinicalInnate Pharma SALymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Neoplasms
Details
FT-538FT-538Phase 2 ClinicalFate Therapeutics IncCoronavirus Disease 2019 (COVID-19); Fallopian Tube Neoplasms; HIV Infections; Leukemia, Monocytic, Acute; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Neoplasms; Ovarian Neoplasms; Peritoneal Neoplasms; Respiratory Distress Syndrome, Adult; Solid tumours
Details
GMA-161GMA-161Phase 1 ClinicalMacrogenics Inc, SanofiPurpura, Thrombocytopenic, Idiopathic
Details
GTB-5550GTB-5550; B7H3 TriKE™; cam1615B7H3; GTB-5550 TriKE™Phase 1 ClinicalUniversity Of MinnesotaSolid tumours
Details
FT-576FT-576Phase 1 ClinicalFate Therapeutics Inc, University Of MinnesotaBone Marrow Neoplasms; Multiple Myeloma
Details
AFM-28AFM-28Phase 1 ClinicalAffimedLeukemia, Myeloid, Acute; Leukemia, Promyelocytic, Acute; Neoplasms
Details
Donor-derived CD123-CD16 bispecific antibody-modified NK cells therapy(Chinese PLA General Hospital)Phase 1 ClinicalPla General HospitalLeukemia, Myeloid, Acute
Details
GTB-3650GTB-3650; GTB-360; OXS-3350; OXS-C3550Phase 1 ClinicalMasonic Cancer Center, University Of MinnesotaBone Marrow Neoplasms; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes
Details
BGB-B3227BGB-B3227Phase 1 ClinicalBeOne Medicines (Beijing) Co LtdGastrointestinal Neoplasms; Lung Neoplasms; Neoplasm Metastasis; Neoplasms; Solid tumours
Details
SM-3321SM-3321; SM3321Phase 1 ClinicalZhuhai StarMab BioMed Technology LtdLeukemia, Myeloid, Acute; Neoplasms
Details
FT-596FT-596Phase 1 ClinicalFate Therapeutics IncLeukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Lymphoma, B-Cell; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin
Details
SAR-443579SAR-443579; SAR443579; SAR'579; IPH6101; IPH-6101Phase 1 ClinicalSanofiBlastic Plasmacytoid Dendritic Cell Neoplasm; Hematologic Diseases; Leukemia, B-Cell; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Precursor Cell Lymphoblastic Leukemia-Lymphoma
Details
FT-516FT-516Phase 1 ClinicalFate Therapeutics Inc, University Of MinnesotaAbdominal Neoplasms; Coronavirus Disease 2019 (COVID-19); Fallopian Tube Neoplasms; Leukemia, Myeloid, Acute; Lymphoma, B-Cell; Ovarian Neoplasms; Solid tumours
Details

Produktrezensionen

  • A***n2025-02-12
    0Menschen mögen
    Acro's Fc gamma receptor proteins are my top choice for Octet binding assays. They consistently deliver reliable results, crucial for accurate research. Their product quality is outstanding, ensuring reproducible experiments. Acro's technical service is exceptional, with a responsive and knowledgeable support team. Their comprehensive range of well-characterized Fc receptor proteins, high purity, and bioactivity have made them my exclusive supplier. The attention to quality control ensures excellent batch-to-batch consistency.
  • W***u2024-10-08
    0Menschen mögen
    We used this biotin labeled protein in the ELISA assay and we have got reproducible and high-quality results. Also I want to mention and there is no degradation or activity changes of this product over more than half year, which made it our experiment easier without bridging assay.
  • J***n2023-06-24
    3Menschen mögen
    We used the biotinylated human Fc gamma RIIIA material from Acro to test the binding of different human antibodies. The material arrived quickly and in time for our experiments. I used the material with the Biacore 8K (SPR) instrument using Series S Biotin CAP chip. We were happy with how the material worked in this assay format. Overall, we were pleased with the quality and would recommend this to other researchers.
Laden Sie mehr
  • Molekülinformation
  • Produktliste
  • Produktrezensionen
  • Klinische Arzneimittelinformation
Kontaktieren Sie uns